LBA34 Single-agent anti-PD-1 balstilimab or in combination with anti-CTLA-4 zalifrelimab for recurrent/metastatic (R/M) cervical cancer (CC): Preliminary results of two independent phase II trials

D.M. O'Malley; A. Oaknin; B.J. Monk; A. Leary; F. Selle; J. Alexandre; L.M. Randall; C. Rojas; M. Neffa; A. Kryzhanivska; L. Gladieff; D. Berton; T. Meniawy; I. Lugowska; I. Bondarenko; K.N. Moore; W.I. Ortuzar Feliu; M. Ancukiewicz; I. Shapiro; I.L. Ray-Coquard

doi:10.1016/j.annonc.2020.08.2264

LBA34 Single-agent anti-PD-1 balstilimab or in combination with anti-CTLA-4 zalifrelimab for recurrent/metastatic (R/M) cervical cancer (CC): Preliminary results of two independent phase II trials

D.M. O'Malley
, A. Oaknin
, B.J. Monk
, A. Leary
, F. Selle
, J. Alexandre
, L.M. Randall
, C. Rojas
, M. Neffa
, A. Kryzhanivska
, L. Gladieff
, D. Berton
, T. Meniawy
, I. Lugowska
, I. Bondarenko
, K.N. Moore
, W.I. Ortuzar Feliu
, M. Ancukiewicz
, I. Shapiro
, I.L. Ray-Coquard

Universidad de los Andes

Producción científica: Contribución a una conferencia › Póster › revisión exhaustiva

Resumen

Background: Second line treatment for R/M CC continues to be a high unmet clinical need. We present data from 2 ph2 trials, of single-agent balstilimab (bal) and in combination with zalifrelimab (zal) in R/M CC.

Idioma original	Español (Chile)
Páginas	S1164-S1165
DOI	https://doi.org/10.1016/j.annonc.2020.08.2264
Estado	Publicada - sep. 2020

ODS de las Naciones Unidas

Este resultado contribuye a los siguientes Objetivos de Desarrollo Sostenible

ODS 3: Salud y bienestar

Acceder al documento

10.1016/j.annonc.2020.08.2264

Otros archivos y enlaces

https://www.mendeley.com/catalogue/aef6cf03-b4cf-3470-9e71-97027e86ab16/

Citar esto

O'Malley, D. M., Oaknin, A., Monk, B. J., Leary, A., Selle, F., Alexandre, J., Randall, L. M., Rojas, C., Neffa, M., Kryzhanivska, A., Gladieff, L., Berton, D., Meniawy, T., Lugowska, I., Bondarenko, I., Moore, K. N., Ortuzar Feliu, W. I., Ancukiewicz, M., Shapiro, I., & Ray-Coquard, I. L. (2020). LBA34 Single-agent anti-PD-1 balstilimab or in combination with anti-CTLA-4 zalifrelimab for recurrent/metastatic (R/M) cervical cancer (CC): Preliminary results of two independent phase II trials. S1164-S1165. https://doi.org/10.1016/j.annonc.2020.08.2264

@conference{3ba3de48481144b2a8a8c031002f492a,

title = "LBA34 Single-agent anti-PD-1 balstilimab or in combination with anti-CTLA-4 zalifrelimab for recurrent/metastatic (R/M) cervical cancer (CC): Preliminary results of two independent phase II trials",

abstract = "Background: Second line treatment for R/M CC continues to be a high unmet clinical need. We present data from 2 ph2 trials, of single-agent balstilimab (bal) and in combination with zalifrelimab (zal) in R/M CC.",

author = "D.M. O'Malley and A. Oaknin and B.J. Monk and A. Leary and F. Selle and J. Alexandre and L.M. Randall and C. Rojas and M. Neffa and A. Kryzhanivska and L. Gladieff and D. Berton and T. Meniawy and I. Lugowska and I. Bondarenko and K.N. Moore and \{Ortuzar Feliu\}, W.I. and M. Ancukiewicz and I. Shapiro and I.L. Ray-Coquard",

year = "2020",

month = sep,

doi = "10.1016/j.annonc.2020.08.2264",

language = "Espa{\~n}ol (Chile)",

pages = "S1164--S1165",

}

O'Malley, DM, Oaknin, A, Monk, BJ, Leary, A, Selle, F, Alexandre, J, Randall, LM, Rojas, C, Neffa, M, Kryzhanivska, A, Gladieff, L, Berton, D, Meniawy, T, Lugowska, I, Bondarenko, I, Moore, KN, Ortuzar Feliu, WI, Ancukiewicz, M, Shapiro, I & Ray-Coquard, IL 2020, 'LBA34 Single-agent anti-PD-1 balstilimab or in combination with anti-CTLA-4 zalifrelimab for recurrent/metastatic (R/M) cervical cancer (CC): Preliminary results of two independent phase II trials', pp. S1164-S1165. https://doi.org/10.1016/j.annonc.2020.08.2264

TY - CONF

T1 - LBA34 Single-agent anti-PD-1 balstilimab or in combination with anti-CTLA-4 zalifrelimab for recurrent/metastatic (R/M) cervical cancer (CC): Preliminary results of two independent phase II trials

AU - O'Malley, D.M.

AU - Oaknin, A.

AU - Monk, B.J.

AU - Leary, A.

AU - Selle, F.

AU - Alexandre, J.

AU - Randall, L.M.

AU - Rojas, C.

AU - Neffa, M.

AU - Kryzhanivska, A.

AU - Gladieff, L.

AU - Berton, D.

AU - Meniawy, T.

AU - Lugowska, I.

AU - Bondarenko, I.

AU - Moore, K.N.

AU - Ortuzar Feliu, W.I.

AU - Ancukiewicz, M.

AU - Shapiro, I.

AU - Ray-Coquard, I.L.

PY - 2020/9

Y1 - 2020/9

N2 - Background: Second line treatment for R/M CC continues to be a high unmet clinical need. We present data from 2 ph2 trials, of single-agent balstilimab (bal) and in combination with zalifrelimab (zal) in R/M CC.

AB - Background: Second line treatment for R/M CC continues to be a high unmet clinical need. We present data from 2 ph2 trials, of single-agent balstilimab (bal) and in combination with zalifrelimab (zal) in R/M CC.

UR - https://www.mendeley.com/catalogue/aef6cf03-b4cf-3470-9e71-97027e86ab16/

U2 - 10.1016/j.annonc.2020.08.2264

DO - 10.1016/j.annonc.2020.08.2264

M3 - Póster

SP - S1164-S1165

ER -